Catalyst

Slingshot members are tracking this event:

Results of the Phase 1 studies showed nine of the 12 drugs tested showed no clinically meaningful reduction in absorption when administered at the same time as Veltassa

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RLYP

100%
AZN

100%

Additional Information

Management Comment
"The results from these studies are encouraging as, of the 12 drugs that had previously shown in vitro binding to Veltassa, nine showed no clinically meaningful reduction in absorption when co-administered with Veltassa in people," said Lance Berman, M.D., chief medical officer of Relypsa. "In addition, when dosing was separated by three hours, there was no impact to absorption of the three drugs that had demonstrated reduced absorption when they were given with Veltassa. We look forward to discussing these data with the FDA and determining next steps."
http://investor.rely...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 15, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1, No Clinical Reduction In Absorbtion, Veltassa